Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06773910 · ClinicalTrials.gov registry record · Phase 2

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

A Phase 2 study of Limited Stage Small Cell Lung Cancer, sponsored by SCRI Development Innovations.

Recruiting
Registry status
Phase 2
Development phase
250
Enrollment target
20
Study locations

NCT06773910 is a Phase 2 study of Limited Stage Small Cell Lung Cancer that is actively recruiting participants, run by SCRI Development Innovations. The registered enrollment target is 250 participants, roughly in line with the 257-participant average among 4 other Limited Stage Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06773910, a Phase 2 study of Limited Stage Small Cell Lung Cancer, is actively recruiting participants, sponsored by SCRI Development Innovations.

RECRUITING
Registry status
Phase 2
Development phase
250 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489

Conditions Studied

Limited Stage Small Cell Lung Cancer

Interventions

  • DRUG Durvalumab
  • DRUG BMS-986489

Study Locations (20)

Florida

  • Florida Cancer Specialists - South - Fort Myers
  • University of Miami - Sylvester Cancer Center - Miami
  • Ocala Oncology Center - Ocala
  • Florida Cancer Specialists - North - Orange City
  • Cancer Care Centers of Brevard - Palm Bay
  • Florida Cancer Specialists - East - West Palm Beach

Illinois

  • Illinois Cancer Specialists - Arlington Heights
  • Illinois Cancer Care - Peoria

Kentucky

  • Baptist Health - Lexington - Lexington
  • Baptist Health - Louisville - Louisville

Ohio

  • Oncology Hematology Care - Cincinnati
  • Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center - Columbus

Alabama

  • Southern Cancer Center - Daphne

California

  • Sansum Clinic - Santa Barbara

Indiana

  • Indiana University Simon Cancer Center - Indianapolis

Minnesota

  • Minnesota Oncology Hematology - Maple Grove

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2025-03-11
Est. Completion 2032-09
Phase Phase 2

Sponsor

SCRI Development Innovations

146 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06773910

The ClinicalTrials.gov registry entry for NCT06773910 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 257-participant average among 4 other Limited Stage Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Limited Stage Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.

NCT06773910 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Illinois, Kentucky.

Frequently Asked Questions

What is clinical trial NCT06773910 about?

NCT06773910 is a clinical study titled "BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)". This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profi...

What is the current status of trial NCT06773910?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-03-11. Estimated completion is 2032-09.

What conditions does trial NCT06773910 study?

This clinical trial studies the following conditions: Limited Stage Small Cell Lung Cancer.

What interventions are being tested in trial NCT06773910?

The interventions under investigation include: Durvalumab (DRUG), BMS-986489 (DRUG).

Who is sponsoring clinical trial NCT06773910?

This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06773910 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Limited Stage Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Limited Stage Small Cell Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.